BSE · 543963
Shelter Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹51 Cr with net profit ₹7 Cr — a 14.28% net margin, versus 15.49% the period before.
Shareholding
As of 2026-05-31
- Promoter44.38%
- Public55.62%
1,089 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.17× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #1 of 30 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,07,995 Cr | 276.76 | 12.39 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,475 Cr | 200.98 | 16.01 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,636 Cr | 68.22 | 13.15 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,317 Cr | 127.37 | 2.14 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,768 Cr | 68.23 | 2.43 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,509 Cr | 34.4 | 4.47 | 12.98% | 11.5% |
| Hikal Limited | ₹2,676 Cr | 185.46 | 2.24 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,234 Cr | 246.74 | 9.13 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,026 Cr | 42.12 | 6.16 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,370 Cr | 69.88 | 3.29 | 17.67% | 13.66% |
| Shelter Pharma Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashShelter Pharma Limited is listed on the Indian markets. The company reported a revenue of Rs 50.67 Cr and a net profit of Rs 7.24 Cr for the fiscal year ending March 2025. As of May 31, 2026, promoter holding stands at 44.38%. The company's market capitalization is Rs 60 Cr.
Positives
- +Revenue has consistently increased from Rs 22.49 Cr in Mar 2021 to Rs 50.67 Cr in Mar 2025.
- +Net profit has grown from Rs 0.04 Cr in Mar 2021 to Rs 7.24 Cr in Mar 2025.
- +The company has a low debt-to-equity ratio of 0.02.
- +No promoter shares are reported as pledged.
Negatives
- −Promoter shareholding decreased from 56.89% in Mar 2023 to 44.38% in May 2026.
- −No DII or FII holding has been reported in the available shareholding data.
- −Key profitability ratios like ROE and ROCE are not available.
- −No quarterly results have been disclosed in the provided data.
Financial Performance
Shelter Pharma Limited has shown consistent revenue growth over the past few years. Revenue increased from Rs 22.49 Cr in Mar 2021 to Rs 50.67 Cr in Mar 2025. Net profit also increased from Rs 0.04 Cr in Mar 2021 to Rs 7.24 Cr in Mar 2025. The company's EBITDA grew from Rs 0.06 Cr in Mar 2021 to Rs 9.80 Cr in Mar 2025.
Profitability & Returns
The company's earnings per share (EPS) grew from Rs 0.88 in Mar 2021 to Rs 6.26 in Mar 2025. Net profit for the fiscal year ending March 2025 was Rs 7.24 Cr. EBITDA for the same period was Rs 9.80 Cr.
Balance Sheet
Shelter Pharma Limited has a low debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing. Specific details regarding assets, liabilities, and equity are not available in the provided data.
Ownership & Pledges
As of May 31, 2026, the promoter holding in Shelter Pharma Limited is 44.38%. Public shareholding is 55.62%. There is no pledged promoter shareholding reported. No shares are held by DIIs or FIIs as of the latest available data.
Regulatory & Surveillance
There is no information provided regarding any surveillance measures or regulatory issues concerning Shelter Pharma Limited.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: May 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.